Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2011-08-16
2011-08-16
Swartz, Rodney P. (Department: 1645)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C424S009100, C424S093100, C424S093200, C424S234100, C424S258100, C435S041000, C435S069100, C435S440000, C536S023100, C536S023700
Reexamination Certificate
active
07998461
ABSTRACT:
Therapeutic methods for treatment of solid tumor cancer cell masses, as can be effected using therapeutic compositions comprisingSalmonellaspecies/strains and related compositions.
REFERENCES:
patent: 6080849 (2000-06-01), Bermudes et al.
patent: 6447784 (2002-09-01), Bermudes et al.
patent: 6475482 (2002-11-01), Bermudes et al.
patent: 6863894 (2005-03-01), Bermudes et al.
patent: 6923972 (2005-08-01), Bermudes et al.
patent: 6962696 (2005-11-01), Bermudes et al.
patent: 7015027 (2006-03-01), Redshaw
patent: 7247296 (2007-07-01), Redshaw
patent: 7354592 (2008-04-01), Bermudes et al.
patent: 7514089 (2009-04-01), Bermudes et al.
patent: 2006/0104955 (2006-05-01), Redshaw
Pawelek, J.M. et al. Bacteria as tumour-targeting vectors. The Lancet Oncology. vol. 4, pp. 548-556, Sep. 2003.
Kasinskas, R.W. et al.Samonella typhimuriumspecifically chemotax and proliferate in heterogenous tumor tissue in vitro. Biotechnology and Bioengineering, vol. 94, No. 4, Jul. 2006.
Kasinskas, RW; Forbes, NS.Salmonella typhimuriumLacking Ribose Chemoreceptors Localize in Tumor Quiescence and Induce Apoptosis. Cancer Res. 2007; 67: (7), Apr. 1, 2007, pp. 3201-3209.
Clairmont, C., et al., “Biodistribution and Genetic Stability of the Novel Antitumor Agent VNP20009, a Genetically Modified Strain ofSalmonella typhimurium,” The Journal of Infectious Diseases181:1996-2002 (2000).
Cunningham, C. and Nemunaitis, J., “A Phase I Trial of Genetically ModifiedSalmonella typhimuriumExpressing Cytosine Deaminase (TAPET-CD), VNP20029) Administered by Intratumoral Injection in Combination With 5-fluorocytosine for Patients With Advanced or Metastatic Cancer,” Protocol No. CL-017, Version: Apr. 9, 2001. 12:1594-1596 (2001).
Forbes, N.S., et al., “Sparse Initial Entrapment of Systemically InjectedSalmonella typhimuriumLeads to Heterogeneous Accumulation Within Tumors,” Cancer Research 63:5188-5193 (2003).
King, I, et al., “Tumor-TargetedSalmonellaExpressing Cytosine Deaminase as an Anticancer Agent,”Human Gene Therapy13:1225-1233 (2002).
Lee, K.C., et al., “Evaluation of the Acute and Subchronic Toxic Effects in Mice, Rats, and Monkeys of the Genetically Engineered andEscherichia coliCytosine Deaminase Gene-IncorporatedSalmonellaStrain, TAPET-CD, Being Developed as an Antitumor Agent,”International Journal of Toxicology20:207-217 (2001).
Low, K.B., et al., Construction of VNP20009, “A Novel, Genetically Stable Antibiotic-Sensitive Strain of Tumor-TargetingSalmonellafor Parenteral Administration in Humans,”Methods in Molecular Medicine 90, 47-59 Suicide Gene Therapy: Methods and Reviews, Ed. C.J. Springer, Humana Press.
Low, K.B., et al., “Lipid a MutantSalmonellaWith Supressed Virulence and TNFα Induction Retain Tumor-Targeting in Vivo,”Nature Biotechnology17:37-41 (1999).
Luo, X., et al., “Genetically ArmedSalmonella typhimuriumDelivered Therpauetic Gene and Inhibited Tumor Growth in Preclinical Models,”Proc Annu Meet Am Assoc Cancer Res42: Abs 3693 (2001).
Luo, X., et al., “Antitumor Effect of VNP20009, an AttenuatedSalmonella, in Murine Tumor Models,”Onoclogy Research12:501-508 (2002).
Mei, S., et al., “Optimization of Tumor-Targeted Gene Delivery by Engineered AttenuatedSalmonella typhimurium,” Anticancer Research22:3261-3266 (2002).
Michl, P. and Gress, T.M., “Bacteria and Bacterial Toxins as Therapeutic Agents for Solid Tumors,”Current Cancer Drug Targets4:689-702 (2004).
Nemunaitis, J., et al., “Pilot Trial of Genetically Modified, AttenuatedSalmonellaExpressing theE. coliCytosine Deaminase Gene in Refractory Cancer Patients,”Cancer Gene Therapy10:737-744 (2003).
Pawelek, J.M., et al., “Tumor TargetedSalmonellaas a Novel Anticancer Vector,”Cancer Research57:4537-4544 (1997).
Toso, J.F., et al., “Phase I Study of the Intravenous Administration of AttenuatedSalmonella typhimuriumto Patients With Metastatic Melanoma,”J. Clin. Oncol. 20(1):142-152 (2001).
Yu, Y.A., et al., “Visualization of Tumors and Metastases in Live Animals With Bacteria and Vaccinia Virus Encoding Light-Emitting Proteins,”Nature Biotechnology22(3):313-320 (2004).
Zhao, M., et al., “Targeted Therapy with aSalmonella TyphimuriumLeucine-Arginine Auxotroph Cures Orthotopic Human Breast Tumors in Nude Mice,”Cancer Res.66(15):7647-7652 (2006).
Zhao, M., et al., “Tumor-Targeting Bacterial Therapy With Amino Acid Auxotrophs of GFP-ExpressingSalmonella typhimurium,” PNAS102(3):755-760 (2005).
Zheng, L., et al., “Tumor Amplified Protein Expression Therapy:Salmonellaas a Tumor-Selective Protein Delivery Vector,”Oncology Research12:127-135 (2000).
Forbes Neil S.
Kasinskas Rachel W.
Hamilton Brook Smith & Reynolds P.C.
Swartz Rodney P.
University of Massachusetts
LandOfFree
Salmonella cancer therapeutics and related therapeutic methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Salmonella cancer therapeutics and related therapeutic methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Salmonella cancer therapeutics and related therapeutic methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2698220